Published: April 2017
Roots Analysis has announced the addition of “Deep Learning in Drug Discovery and Diagnostics, 2017-2035” report to its list of offerings. The report provides a comprehensive analysis of the current landscape and future outlook of the growing market of deep learning solutions within the healthcare domain.
Rohit Kumar, the principal analyst stated that, “Various deep learning solutions are currently available / being developed to cater to unmet medical needs and generate relevant insights from medical data. These solutions are anticipated to open up significant opportunities in the field of drug discovery and diagnostics as the healthcare industry gradually shifts towards digital solutions.”
One of the primary objectives of the study was to project the growth of this market segment and evaluate the future prospects of deep learning within the healthcare industry. Amongst other things, the study covers the following:
Kumar further added, “The likely benefits associated with the use of deep learning based solutions in drug discovery and diagnostics are estimated to be worth multi billion dollars. There are well-known references where deep learning models have accelerated the drug discovery process and provided solutions to precision medicine. With potential applications in drug repurposing and preclinical research, deep learning in drug discovery is likely to offer immense opportunity. Similarly, in diagnostics, an increase in the speed of diagnosis is likely to have a profound impact in regions with large patient to physician ratios. The implementation of such solutions is anticipated to increase the efficiency of physicians, providing a certain amount of relief to the overly-burdened global healthcare system.”
The report highlights the contributions of several players in the field; some of the examples are listed below:
The opinions and insights discussed in this report were influenced by valuable inputs from senior stakeholders in the industry. The report features detailed transcripts of interviews held with Mausumi Acharya (CEO, Advenio Technosys), Carla Leibowitz (Head of Strategy and Marketing, Arterys) and Deekshith Marla (CTO, Arya.ai).
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/deep-learning-in-drug-discovery-and-diagnostics-2017-2035/156.html or email firstname.lastname@example.org
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES